PRP effect on ovary

Evaluation of the effect of intraovarian platelet rich plasma injection on ovarian folliculogenesis and intracytoplasmic sperm injection outcome in poor responders- Quasi-Experimental Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180528039878N5

Enrollment

Registered

2024-03-04

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary ovarian failure. Primary ovarian failure

Interventions

Intervention group: Intraovarian injection of platelet-rich plasma - 8.5 ml of peripheral venous blood will be drawn into a 10 ml syringe containing 1.5 ml of anticoagulant solution. According to the

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age less than 40 years The number of antral follicles is less than 5 Anti-Müllerian hormone level less than 0.3 nano-grams/milliliter

Exclusion criteria

Exclusion criteria: Women with autoimmune disorders Anemia Thrombophilic disorders Current cancer or medical history of cancer Severe male infertility Endometriosis

Design outcomes

Primary

Measure	Time frame
The total number of oocytes retrieved. Timepoint: The day of ovarian puncture before platelet rich plasma injection, The day of ovarian puncture after platelet rich plasma injection. Method of measurement: According to the count.;The total number of metaphase II oocytes. Timepoint: The day of ovarian puncture before platelet rich plasma injection, The day of ovarian puncture after platelet rich plasma injection. Method of measurement: According to the count.	—

Measure

Time frame

The total number of oocytes retrieved. Timepoint: The day of ovarian puncture before platelet rich plasma injection, The day of ovarian puncture after platelet rich plasma injection. Method of measurement: According to the count.;The total number of metaphase II oocytes. Timepoint: The day of ovarian puncture before platelet rich plasma injection, The day of ovarian puncture after platelet rich plasma injection. Method of measurement: According to the count.

—

Secondary

Measure	Time frame
Basal level of Anti-Müllerian Hormone. Timepoint: Serum level on the third day of the menstrual cycle before platelet-rich plasma injection, Serum level on the third day of the menstrual cycle after platelet-rich plasma injection. Method of measurement: Using the test kit.;Number of embryos. Timepoint: In the cycle before platelet-rich plasma injection, In the cycle after platelet-rich plasma injection. Method of measurement: According to the count.	—

Measure

Time frame

Basal level of Anti-Müllerian Hormone. Timepoint: Serum level on the third day of the menstrual cycle before platelet-rich plasma injection, Serum level on the third day of the menstrual cycle after platelet-rich plasma injection. Method of measurement: Using the test kit.;Number of embryos. Timepoint: In the cycle before platelet-rich plasma injection, In the cycle after platelet-rich plasma injection. Method of measurement: According to the count.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Mehrafza

Mehr Medical Institute

marzieh.mehrafza@gmail.com+98 13 3376 4270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026